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j ourna l homepage: www.eb iomed ic ine.comEditorialTreating the Inﬂammatory Core of Metabolic SyndromesDiabetes UK announced on August 17th, 2015 that the number of
people living with diabetes in the UK has increased by nearly 60%
in the past ten years. Diabetes is also on the rise in theUS,with the num-
ber of conﬁrmed cases more than tripling between 1980 and 2011 ac-
cording to the US Centers for Disease control and Prevention (CDC).
Worldwide, about 347 million people suffer from this disease,
with the vast majority of these cases being attributed to type 2 diabetes
(T2D). And in 2012, approximately 1.5 million deaths were directly
caused by diabetes according to theWorld Health Organization (WHO).
Along with the ever-increasing prevalence of diabetes, cardiovascu-
lar disease (CVD) remains the number one cause of mortality world-
wide, accounting for more than 31% of all global deaths in 2012
(WHO). According to most recent data from the CDC, about 1 in every
4 deaths in the US is currently related to heart disease. Diabetes and
CVD are also connected: adults with diabetes are twice to four times
as likely to develop CVD than those without diabetes, according to the
American Heart Association.
Intertwined with both of these human health catastrophes is the
obesity epidemic. Obesity is known to have direct connections to both
diabetes and CVD, and it is becoming a global crisis—with more than
600 million people affected around the world, according to 2014 WHO
data. Obesity is clearly no longer simply a “ﬁrst-world” problem.
Metabolic syndrome broadly refers to a set of obesity-related condi-
tions, such as insulin resistance and high-blood pressure, which predis-
pose the patient to increased risk of developing T2D and CVD. What do
we know about themechanistic connections between obesity, diabetes,
and CVD, and how can we intervene therapeutically? Several candidate
pathways including oxidative stress have emerged as potential
targets—with dysregulated reactive oxygen species linked to both
insulin-producing pancreatic β-cell failure and cardiovascular disor-
ders. Alterations in the microbiome are also thought to play a role in
the metabolic dysregulations associated with obesity. Central to many
candidate pathways, however, is a generalized predisposition in the
obese patient toward a pro-inﬂammatory state—including a shift from
anti-inﬂammatory (M2)macrophages to a pro-inﬂammatory (M1) pro-
ﬁle, a decrease in anti-inﬂammatory regulatory T (Treg) cells in the ad-
ipose tissue, and release of pro-inﬂammatory cytokines directly from
the adipocytes.
Pro-inﬂammatory cytokines such as interleukin-1β (IL-1β), IL-6
and TNFα are all elevated in obese and T2Dpatients, and some studies in-
dicate a direct pathogenic role for suchmolecules in β-cell destruction. In
addition to hypertension and dyslipidemia, emerging evidence suggests
that the increased inﬂammation associated with T2D may also directly
contribute to the well-documented link between diabetes and CVD.
Managing blood sugar, cholesterol and lipid levels remains the ﬁrst
line of management against these metabolic disorders. However, if T2Dhttp://dx.doi.org/10.1016/j.ebiom.2015.09.011
2352-3964/© 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NCand CVD are essentially inﬂammatory conditions, would addressing this
inﬂammatory core ameliorate symptoms and result in better outcome
for patients?
Multiple recent clinical trials have shown that inhibiting IL-1β sig-
naling with anakinra or humanized blocking antibodies (such as
gevokizumab or canakinumab) results in a long-term improvement in
insulin sensitivity and secretion, and an overall reduction in inﬂamma-
tion. Research is currently underway to determine whether the Nlrp3
inﬂammasome, which is upstream of IL-1 production and controls its
processing and release, may also be a worthwhile target for the treat-
ment of diabetes. Several short-duration clinical studies using TNFα an-
tagonists have not yet found a clear association between blocking TNFα
signaling and increased insulin-sensitivity. However, clues from other
large-scale clinical trials using TNFα to treat, for example, rheumatoid
arthritis show a signiﬁcant decrease in the development of T2D with
treatment. Targeting TNFαmay therefore also be worth investigating
further as a treatment option for diabetic patients. Recent preclinical
studies using a mouse model of T2D have revealed that administration
of the anti-inﬂammatory cytokine IL-33 resulted in a boost in Treg cell
populations speciﬁcally in the adipose tissue. Inﬂammation was re-
duced, and glucose tolerance was restored in the IL-33-treated animals,
providing further evidence that targeting inﬂammatory pathways may
have a beneﬁcial effect for diabetic patients.
Heart disease and atherosclerosis, long thought to depend in part on
lipid imbalance, are also likely to depend heavily on the inﬂammatory
state of the individual. The inﬂammation theory of CVD is now rapidly
gaining traction, and studies are well underway to determine if modu-
lating the inﬂammatory pathways dysregulated bymetabolic imbalance
may improve cardiovascular health. For example, phase III of the large-
scale international Canakinumab Anti-inﬂammatory Thrombosis Out-
comes Study (CANTOS) aims to determine whether blockade of IL-1β
can reduce the rates of adverse cardiac events in patients with coronary
artery disease and high levels of C-reactive protein (CRP), an inﬂamma-
tory marker. A second study, the Cardiovascular Inﬂammation Reduc-
tion Trial (CIRT) also aims to test the premise of inﬂammation theory
by treating post-myocardial infarction patients who have either
diabetes or metabolic syndrome with methotrexate—a drug which has
been shown to reduce IL-6, TNF and CRP. Both of these long-term,
large-scale studies are still ongoing, and will soon provide much-
anticipated data on whether blocking inﬂammation can help prevent
atherothrombotic events.
Although genetic and large-scale observational studies have demon-
strated a deﬁnitive association between increased IL-6 expression levels
and risk for CVD, targeting IL-6 signaling—for example by using the hu-
manized anti-IL-6R antibody tocilizumab—is likely to be complicated by
the fact that IL-6 may have both pro- and anti-inﬂammatory roles in-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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which it will be possible to uncouple these IL-6 functions to confer ther-
apeutic beneﬁts.
Obesity and its associated consequences of metabolic dysregulation
continue to grow as aworld-widehealth crisis. Lifestyle changes, includ-
ing adopting a healthy diet and regular exercise, naturally remain thesimplest approach to combating this epidemic. However, better clinical
interventions for T2D and CVD patients are still needed, and while
they are clearly multifactorial in their etiology, targeting metabolic syn-
dromes at their inﬂammatory core seems a promising idea well worth
pursuing.
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